An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F14%3A43909178" target="_blank" >RIV/00216208:11120/14:43909178 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064173:_____/14:N0000004

Výsledek na webu

<a href="http://dx.doi.org/10.1185/03007995.2014.944638" target="_blank" >http://dx.doi.org/10.1185/03007995.2014.944638</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1185/03007995.2014.944638" target="_blank" >10.1185/03007995.2014.944638</a>

Jazyk výsledku

angličtina

Název v původním jazyce

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel

Popis výsledku v původním jazyce

In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14.5 (maximum of 15) months. Based on this trial, the EU label for prasugrel recommends treatment for up to 12 months andexcludes patients with prior stroke/transient ischemic attack (TIA). Furthermore, the EU label recommends the 10 mg maintenance dose (MD) for patients with body weight >=60 kg and age <75 years. A lower MD of 5 mg is recommended for those with body weight <60 kg; although generally not recommended, 5 mg can be prescribed to patients >=75 years after individual risk-benefit evaluation. This paper presents the one-year outcome data for this 10 mg indicated cohort. METHODS AND RESULTS: From the overall cohort of 13,608 patients in TRITON-TIMI 38, 10,804 fulfilled inclusion criteria for the 10 mg indicated cohort, of whom 22% had a history of diabetes, 73% an index diagnosis of unstable angina/non-ST-segment-elevation myocardial infarction

Název v anglickém jazyce

An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel

Popis výsledku anglicky

In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14.5 (maximum of 15) months. Based on this trial, the EU label for prasugrel recommends treatment for up to 12 months andexcludes patients with prior stroke/transient ischemic attack (TIA). Furthermore, the EU label recommends the 10 mg maintenance dose (MD) for patients with body weight >=60 kg and age <75 years. A lower MD of 5 mg is recommended for those with body weight <60 kg; although generally not recommended, 5 mg can be prescribed to patients >=75 years after individual risk-benefit evaluation. This paper presents the one-year outcome data for this 10 mg indicated cohort. METHODS AND RESULTS: From the overall cohort of 13,608 patients in TRITON-TIMI 38, 10,804 fulfilled inclusion criteria for the 10 mg indicated cohort, of whom 22% had a history of diabetes, 73% an index diagnosis of unstable angina/non-ST-segment-elevation myocardial infarction

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Medical Research and Opinion

ISSN

0300-7995

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

13

Strana od-do

2193-2205

Kód UT WoS článku

000344606300006

EID výsledku v databázi Scopus

—